Protagonist Therapeutics, Inc (PTGX) Stock
PTGX has an Alpha Score of 47 out of 100 (weak), computed on Nov 6, 2026 from 3 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported PTGX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Duquesne Family Office's at $25.61M. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 109.1 and its net margin 29.4% (key statistics as of Oct 23, 2026).
What is PTGX's Alpha Score?
How it works →Alpha Score of 46 reflects weak overall profile with moderate momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own PTGX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Duquesne Family Office Stanley Druckenmiller | 209K | $25.61M | +31% |
| Marshall Wace | 109K | $13.36M | -83% |
| Bridgewater Associates Ray Dalio | 9K | $1.14M | +76% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Protagonist Therapeutics, Inc insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Ali Asif | Chief Financial Officer | SELL | 12.6K | $1.8M |
| Sep 30, 26 | Ali Asif | Chief Financial Officer | SELL | 46.0K | $6.5M |
| Sep 10, 26 | Patel Dinesh V Ph D | President and CEO | SELL | 7.3K | $1.0M |
| Sep 9, 26 | Patel Dinesh V Ph D | President and CEO | SELL | 63.5K | $9.3M |
| Sep 8, 26 | Patel Dinesh V Ph D | President and CEO | SELL | 54.2K | $7.9M |
| Aug 11, 26 | Patel Dinesh V Ph D | President and CEO | SELL | 34.2K | $5.1M |
| Aug 10, 26 | Patel Dinesh V Ph D | President and CEO | SELL | 65.8K | $9.8M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are PTGX's key statistics?
Key statistics as of Oct 23, 2026
How does PTGX's valuation compare with the Healthcare sector?
| Metric | PTGX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 109.1 | 28.8 | 111 |
| Net margin | 29.40% | 4.31% | 164 |
| Return on equity | 12.03% | 5.47% | 185 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
PTGX price chart
Powered by TradingViewWhat does Protagonist Therapeutics, Inc do?
Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company targets unmet medical needs in areas such as hematology, blood disorders, inflammation, immunology, and metabolic diseases. Key pipeline candidates include rusfertide, an injectable hepcidin mimetic in phase 3 clinical trials for polycythemia vera; icotrokinra (formerly JNJ-2113), an orally delivered investigational drug in phase 3 trials for plaque psoriasis and inflammatory diseases; and PN-943, an oral gut-restricted integrin antagonist that has completed phase 2 trials for ulcerative colitis. Additional programs encompass oral IL-17 antagonists like PN-881, obesity treatments, and iron metabolism disorders, advanced through internal efforts and collaborations with partners including Johnson & Johnson and Takeda. Protagonist Therapeutics Inc. plays a vital role in the biotechnology sector by pioneering oral peptide alternatives to injectable therapies for immune-mediated skin diseases and rare blood conditions. Founded in 2006 and headquartered in Newark, California, it focuses on advancing innovative treatments to improve patient outcomes in challenging therapeutic areas.